Clinical profile and outcome of cardiac involvement in MELAS syndrome.


Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
01 Feb 2019
Historique:
received: 26 08 2018
revised: 02 10 2018
accepted: 15 10 2018
pubmed: 30 11 2018
medline: 28 8 2019
entrez: 29 11 2018
Statut: ppublish

Résumé

Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like (MELAS) syndrome is a rare condition with heterogeneous clinical presentation. Cardiac involvement commonly develops during adulthood, comprising both structural and conduction/arrhythmic abnormalities; early paediatric onset has rarely been reported. We describe the clinical profile, outcome and clinical implication of MELAS-associated cardiomyopathy at a tertiary referral centre. From 2000 to 2016 we enrolled 21 patients affected by genetically-proven MELAS. Patients were followed-up at least annually over a mean of 8.5 years. All patients carried the MT-TL1 3243A>G mutation. Cardiac involvement was documented in 8 (38%) patients (three <18 years; five ≥18 years), including 6 (75%) with hypertrophic cardiomyopathy, 1 (12.5%) with dilated cardiomyopathy, and 1 (12.5%) with persistent pulmonary hypertension. During follow-up, 3 patients died, all with cardiac onset <18 years. The cause of death, however, was non-cardiac (infections, respiratory failure, stroke). Neither events nor cardiac progression were recorded among patients with onset ≥18 years. Adult cardiologists were responsible for 5/8 of referrals, even in patients with long-standing extra-cardiac involvement. Cardiac involvement was found in over 1/3 of patients with MELAS syndrome, and exhibited a bimodal age-related distribution with distinct final outcomes. Paediatric-onset cardiomyopathy represented a hallmark of systemic disease severity, without being the main determinant of outcome. Conversely, adult-onset cardiomyopathy appeared to represent a mild and non-progressive mid-term manifestation. Adult cardiologists played an important role in the diagnostic process, triggering suspicion of MELAS in most of patients diagnosis >18 years.

Sections du résumé

BACKGROUND BACKGROUND
Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like (MELAS) syndrome is a rare condition with heterogeneous clinical presentation. Cardiac involvement commonly develops during adulthood, comprising both structural and conduction/arrhythmic abnormalities; early paediatric onset has rarely been reported. We describe the clinical profile, outcome and clinical implication of MELAS-associated cardiomyopathy at a tertiary referral centre.
METHODS METHODS
From 2000 to 2016 we enrolled 21 patients affected by genetically-proven MELAS. Patients were followed-up at least annually over a mean of 8.5 years.
RESULTS RESULTS
All patients carried the MT-TL1 3243A>G mutation. Cardiac involvement was documented in 8 (38%) patients (three <18 years; five ≥18 years), including 6 (75%) with hypertrophic cardiomyopathy, 1 (12.5%) with dilated cardiomyopathy, and 1 (12.5%) with persistent pulmonary hypertension. During follow-up, 3 patients died, all with cardiac onset <18 years. The cause of death, however, was non-cardiac (infections, respiratory failure, stroke). Neither events nor cardiac progression were recorded among patients with onset ≥18 years. Adult cardiologists were responsible for 5/8 of referrals, even in patients with long-standing extra-cardiac involvement.
CONCLUSIONS CONCLUSIONS
Cardiac involvement was found in over 1/3 of patients with MELAS syndrome, and exhibited a bimodal age-related distribution with distinct final outcomes. Paediatric-onset cardiomyopathy represented a hallmark of systemic disease severity, without being the main determinant of outcome. Conversely, adult-onset cardiomyopathy appeared to represent a mild and non-progressive mid-term manifestation. Adult cardiologists played an important role in the diagnostic process, triggering suspicion of MELAS in most of patients diagnosis >18 years.

Identifiants

pubmed: 30482630
pii: S0167-5273(18)34949-0
doi: 10.1016/j.ijcard.2018.10.051
pii:
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

14-19

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2018 Elsevier B.V. All rights reserved.

Auteurs

Alice Brambilla (A)

University of Florence, Anna Meyer Children's Hospital, viale Pieraccini 24, 50139 Florence, Italy. Electronic address: alice.brambilla@unifi.it.

Silvia Favilli (S)

Paediatric Cardiology Unit, Anna Meyer Children's Hospital, viale Pieraccini 24, 50139 Florence, Italy. Electronic address: s.favilli@meyer.it.

Iacopo Olivotto (I)

Cardiomyopathy Unit, Careggi Hospital, Largo Brambilla 3, Florence, Italy.

Giovanni Battista Calabri (GB)

Paediatric Cardiology Unit, Anna Meyer Children's Hospital, viale Pieraccini 24, 50139 Florence, Italy.

Giulio Porcedda (G)

Paediatric Cardiology Unit, Anna Meyer Children's Hospital, viale Pieraccini 24, 50139 Florence, Italy.

Luciano De Simone (L)

Paediatric Cardiology Unit, Anna Meyer Children's Hospital, viale Pieraccini 24, 50139 Florence, Italy. Electronic address: l.desimone@meyer.it.

Elena Procopio (E)

Department of Inherited Neuro-metabolic Disorders, Anna Meyer Children's Hospital, viale Pieraccini 24, 50159 Florence, Italy. Electronic address: e.procopio@meyer.it.

Elisabetta Pasquini (E)

Department of Inherited Neuro-metabolic Disorders, Anna Meyer Children's Hospital, viale Pieraccini 24, 50159 Florence, Italy. Electronic address: e.pasquini@meyer.it.

Maria Alice Donati (MA)

Department of Inherited Neuro-metabolic Disorders, Anna Meyer Children's Hospital, viale Pieraccini 24, 50159 Florence, Italy. Electronic address: maria.donati@meyer.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH